Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Horizon Therapeutics

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

StockNews.com

Amgen cuts Horizon Therapeutics jobs at Deerfield office after acquisition

350 people will be laid off, many of them at Horizon’s U.S. base in Deerfield.

Chicago Sun-Times

Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade

Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

StockNews.com

Why Amgen's $28 Billion Merger News Also Bodes Well For Pfizer, Biogen

Amgen stock rose Friday after the FTC dropped its lawsuit, clearing the way for the biotech to buy Horizon Therapeutics for $28 billion.

Investors Business Daily

Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle

The FTC pulled back one of its efforts to block Amgen's Horizon buyout, according to a document released Friday that sent HZNP stock flying on Monday.

Investors Business Daily

Stocks Undercut as Little Progress is seen in U.S. Debt Ceiling Talks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up +0.09%. Stock indexes Tuesday settled mixed, with the Dow Jones...

Barchart

Read news from The Economist, FT, and more,
with one subscription

US sues to block $28 bn Amgen biopharma acquisition

New York (AFP) - US regulators filed a lawsuit Tuesday to block biopharmaceutical firm Amgen's proposed $28 billion takeover of drug maker Horizon Therapeutics, saying the transaction would harm consumers.

AFP

Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon

Federal regulators are suing to block biotech drug developer Amgen’s more than $26 billion deal for Horizon Therapeutics

The Independent UK

Stocks Mixed as Debt Ceiling Talks Resume

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. U.S. stocks this morning are mixed, with the Dow...

Barchart

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Barchart

Stocks Slip Lower, Retail Sales On Deck, Home Depot Earnings, Buffett Adds Capital One, Horizon Therapeutics Deal In Doubt - 5 Things To Know

Stock futures slip lower with debt ceiling talks in focus; Retail sales on deck after consumers powered Q1 GDP growth; Home Depot earnings in focus as retail week heats up; Warren Buffett's Berkshire Hathaway takes new position in Capital One and Horizon Therapeutics plunges on report FTC will sue to…

The Street

How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own

Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

The Federal Trade Commission

144 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.